We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Zhejiang Medicine Co. Ltd. has terminated its Phase III oncology trial for oral forms of prochloridine mesylate to treat acute myeloid leukemia due to a lack of efficacy.